Expression of hypoxia-inducible factor 1α in thyroid carcinomas

Endocrine-Related Cancer

Volumn 17, Issue 1, 2010, Pages 61-72

  Burrows, N ^a   Resch, J ^a   Cowen, R L ^a   Von Wasielewski, R ^b   Hoang Vu, C ^c   West, C M ^a   Williams, K J ^a   Brabant, G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CARBONATE DEHYDRATASE IX; COBALT CHLORIDE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAF PROTEIN;

ARTICLE; CANCER THERAPY; CELL DEDIFFERENTIATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; PHENOTYPE; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROID CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA, FOLLICULAR; ANAEROBIOSIS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA; CARCINOMA, PAPILLARY; CELL HYPOXIA; CELL LINE, TUMOR; CHROMONES; COBALT; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MORPHOLINES; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 77449147772     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0251     Document Type: Article

References (34)

1. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM & Stratford IJ 2003 GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. International Journal of Cancer 104 85-91.
2. Allred CD, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK & McGuire WL 1993 Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. Journal of the National Cancer Institute 85 200-206.
3. Bárdos JI & Ashcroft M 2005 Negative and positive regulation of HIF-1: a complex network. Biochimica et Biophysica Acta 1755 107-120.
4. Belge G, Garcia E, de Jong P, Bartnitzke S & Bullerdiek J 1995 FISH analyses of a newly established thyroid tumor cell line showing at (1;19) (p35 or p36.1; q13) reveal that the breakpoint lies between 19q13.3-13.4 and 19q13.4. Cytogenetics and Cell Genetics 69 220-222.
5. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA, Stratford IJ & Williams KJ 2006 Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia-inducible factor-1. Molecular Pharmacology 69 411-418.
6. Chadderton N, Cowen RL, Robinson S, Greco O, Scott SD, Stratford IJ, Patterson AV & Williams KJ 2005 Dual responsive promoters to target therapeutic gene expression to radiationresistant hypoxic tumour cells. International Journal of Radiation Oncology, Biology, Physics 62 213-222.
7. Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC & Pouysségur J 2009 Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Research 69 358-368.
8. Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind S & Stratford IJ 2004 Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Research 64 1396-1402.
9. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A et al. 2007 Mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 92 2840-2843.
10. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A & Basolo F 2008 Braf V600E mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Journal of Clinical Endocrinology and Metabolism 93 3943-3949.
11. Garcia JA 2006 HIFing the brakes: therapeutic opportunities for treatment of human malignancies. Science's STKE 2006 25.
12. Heilig C, Brosius F, Siu B, Concepcion L, Mortensen R, Heilig K, Zhu M, Weldon S, Wu G & Conner D 2003 Implications of glucose transporter protein type 1 (GLUT1)-haplodeficiency in embryonic stem cells for their survival in response to hypoxic stress. American Journal of Pathology 163 1874-1885.
13. Hou P, Liu D, Shan Y, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V et al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 13 1161-1170.
14. Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW & Hillan KJ 2004 Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. Journal of Clinical Pathology 57 504-512.
15. Kim YW, Do IG & Park YK 2006 Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathology, Research and Practice 202 759-765.
16. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457.
17. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306.
18. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M & Xu X 2007 Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Research 67 3177-3184.
19. Lee JH, Lee ES & Kim YS 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110 38-46.
20. Moeller BJ & Dewhirst MW 2004 Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 3 1107-1110.
21. Paes JE & Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinology and Metabolism Clinics of North America 37 375-387.
22. Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA & Mitsiades N 2003 Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5392-5398.
23. Pouyssegur J, Dayan F & Mazure NM 2006 Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 437-443.
24. Schonberger J, Ruschoff J, Grimm D, Marienhagen J, Rümmele P, Meyringer R, Kossmehl P, Hofstaedter F & Eilles C 2002 Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 12 747-754.
25. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC et al. 2008 DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 93 4331-4341.
26. Shafee N, Kaluz S, Ru N & Stanbridge EJ 2009 PI3K/Akt, activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Letters 282 109-115.
27. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ & Olive P 2005 Reduced expression of hypoxia-inducible factor-1A in perinecrotic regions of solid tumors. Cancer Research 65 7260-7266.
28. Tuttle RM, Fleisher M, Francis GL & Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. Journal of Clinical Endocrinology and Metabolism 87 1737-1742.
29. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM & Wenger RH 2003 The hypoxia-inducible factor-1α is a negative factor for tumor therapy. Oncogene 22 3213-3220.
30. Vordermark D, Kaffer A, Riedl S, Katzer A & Flentje M 2005 Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. International Journal of Radiation Oncology, Biology, Physics 61 1197-1207.
31. Weng LP, Gimm O, Kum JB, Smith WM, Zhou XP, Wynford-Thomas D, Leone G & Eng C 2001 Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Human Molecular Genetics 10 251-258.
32. Williams KJ, Telfer BA, Xenaki D, Sheridan MR, Peters HPW, Honess D, Dachs GU, Harris AL, van der Kogel A & Stratford IJ 2005 Enhanced response to radiotherapy in tumours deficient in hypoxia-inducible factor-1α. Radiotherapy and Oncology 75 89-98.
33. Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research 63 4561-4567.
34. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T & Osamura Y 2005 Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncology Reports 14 1499-1504.